Trulieve: As Regulatory Headwinds Wane, Value Creation Is On The Cards (NYSE:TRLV)
· seekingalpha.com
Trulieve Cannabis is reinitiated as a Buy, driven by regulatory catalysts and attractive valuation after a recent 81% rally. Click for this TRLV update.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions...